...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Oncology >Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
【24h】

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.

机译：CHOP联合利妥昔单抗联合治疗显着改善了不列颠哥伦比亚省弥漫性大B细胞淋巴瘤的预后。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: For more than two decades, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has been the standard therapy for diffuse large B-cell lymphoma (DLBCL). The addition of rituximab to CHOP has been shown to improve outcome in elderly patients with DLBCL. We conducted a population-based analysis to assess the impact of this combination therapy on adult patients with DLBCL in the province of British Columbia (BC). METHODS: We compared outcomes during a 3-year period; 18 months before (prerituximab) and 18 months after (postrituximab) institution of a policy recommending the combination of CHOP and rituximab for all patients with newly diagnosed advanced-stage (stage III or IV or stage I or II with "B" symptoms or bulky [> 10 cm] disease) DLBCL. RESULTS: A total of 292 patients were evaluated; 140 in the prerituximab group (median follow-up, 42 months) and 152 in the postrituximab group (median follow-up, 24 months). Both progression-free survival (risk ratio, 0.56; 95% CI, 0.39 to 0.81; P = .002) and overall survival (risk ratio, 0.40; 95% CI, 0.27 to 0.61, P < .0001) were significantly improved in the postrituximab group. After controlling for age and International Prognostic Index score, era of treatment remained a strong independent predictor of progression-free survival (risk ratio, 0.59; 95% CI, 0.41 to 0.85; P = .005) and overall survival (risk ratio, 0.43; 95% CI, 0.29 to 0.66; P < .001). The benefit of treatment in the postrituximab era was present regardless of age. CONCLUSION: The addition of rituximab to CHOP chemotherapy has resulted in a dramatic improvement in outcome for DLBCL patients of all ages in the province of BC.
机译：目的：二十多年来，环磷酰胺，阿霉素，长春新碱和泼尼松（CHOP）已成为弥漫性大B细胞淋巴瘤（DLBCL）的标准疗法。已显示在CHOP中加入利妥昔单抗可改善老年DLBCL患者的预后。我们进行了一项基于人群的分析，以评估这种联合治疗对不列颠哥伦比亚省（BC）成年DLBCL患者的影响。方法：我们比较了三年期间的结果;对于所有新诊断为晚期（III期或IV期或I期或II期为“ B”症状或体征较大的）新患者，应制定政策建议在利妥昔单抗前18个月和利妥昔单抗后18个月的政策建议[> 10 cm]疾病）DLBCL。结果：共评估了292例患者。利妥昔单抗前组140例（中位随访42个月），利妥昔单抗后组152例（中位随访24个月）。无进展生存期（风险比0.56; 95％CI，0.39至0.81; P = .002）和总体生存率（风险比，0.40; 95％CI，0.27至0.61，P <.0001）均得到显着改善。利妥昔单抗组。在控制了年龄和国际预后指数得分之后，治疗时代仍然是无进展生存（风险比，0.59; 95％CI，0.41至0.85; P = .005）和总体生存（风险比，0.43）的强有力的独立预测因子。 ; 95％CI，0.29至0.66; P <.001）。无论年龄大小，都存在利妥昔单抗时代治疗的益处。结论：在CHOP化疗中加入利妥昔单抗已使不列颠哥伦比亚省所有年龄段的DLBCL患者的预后都有显着改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号